Liaoning Cheng Da (600739) Fundamentals 2026 — P/E 17.6x, Revenue Analysis | SniperIQ
Liaoning Cheng Da (600739) is a CN-listed Healthcare company in Medical - Distribution with a market capitalization of ¥16.6B, trading at ¥10.92 on the SHH. This SniperIQ fundamentals page covers Liaoning Cheng Da's valuation (P/E 17.6x, P/B 0.6x), profitability (net margin 10.1%), revenue (¥9.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Liaoning Cheng Da's market cap?
Liaoning Cheng Da (600739) has a market capitalization of approximately ¥16.6B, trading at ¥10.92 on the SHH. Market cap moves with the live share price.
What is Liaoning Cheng Da's P/E ratio?
Liaoning Cheng Da's trailing twelve-month P/E ratio is 17.6x, with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Liaoning Cheng Da?
Liaoning Cheng Da runs a net profit margin of 10.1%, a gross margin of 12.9%, and an operating margin of -11.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Liaoning Cheng Da generate?
Liaoning Cheng Da reported revenue of ¥9.9B for fiscal year 2025, with net income of ¥737M and earnings per share (EPS) of 0.48. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Liaoning Cheng Da pay a dividend?
Liaoning Cheng Da offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Liaoning Cheng Da financially healthy?
Liaoning Cheng Da carries a debt-to-equity ratio of 0.48x and a current ratio of 1.40x, with a market beta of 0.72. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Liaoning Cheng Da a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Liaoning Cheng Da (600739) the key facts are: market cap ¥16.6B, P/E 17.6x, revenue ¥9.9B, 52-week range 9.84-13.58. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Liaoning Cheng Da's full fundamentals live
Get Liaoning Cheng Da's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.